Abbott Laboratories (ABT)vsAlamar Biosciences, Inc. Common Stock (ALMR)
ABT
Abbott Laboratories
$101.95
-1.36%
HEALTHCARE · Cap: $176.41B
ALMR
Alamar Biosciences, Inc. Common Stock
$27.89
+0.43%
HEALTHCARE · Cap: $2.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 46290% more annual revenue ($46.59B vs $100.42M). ABT leads profitability with a 11.7% profit margin vs -49.4%. ABT earns a higher WallStSmart Score of 54/100 (C-).
ABT
Buy54
out of 100
Grade: C-
ALMR
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.5%
Fair Value
$74.13
Current Price
$101.95
$27.82 premium
Intrinsic value data unavailable for ALMR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Generating 2.1B in free cash flow
Revenue surging 82.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
0.0% earnings growth
ROE of -33.6% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : ALMR
The strongest argument for ALMR centers on Revenue Growth, Debt/Equity. Revenue growth of 82.1% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : ALMR
The primary concerns for ALMR are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
ABT profiles as a value stock while ALMR is a hypergrowth play — different risk/reward profiles.
ALMR is growing revenue faster at 82.1% — sustainability is the question.
ABT generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABT scores higher overall (54/100 vs 28/100) and 13.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Alamar Biosciences, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases utilizing its proprietary technology platform. The company is recognized for its ability to provide rapid and precise testing, which enhances clinical decision-making and improves patient outcomes. With a strong commitment to ongoing research and development, Alamar is well-positioned to address pressing medical needs, making it an appealing investment opportunity for institutional investors looking to capitalize on growth within the expanding diagnostics market.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?